Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Dienestrol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 known ✓ | P03372 | 7/20 | 0.85 |
| ▸ | MAPT | P10636 | 5/20 | 0.85 |
| ▸ | LMNA | P02545 | 4/20 | 0.85 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.85 |
| ▸ | MEN1 | O00255 | 3/20 | 0.85 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.85 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.85 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.85 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.85 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.85 |
| ▸ | TP53 | P04637 | 2/20 | 0.85 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.85 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.85 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.85 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.85 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.85 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.85 |
| ▸ | GAA | P10253 | 1/20 | 0.85 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.85 |
| ▸ | CA12 | O43570 | 5/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dienestrol SCHEMBL2896853 | 0.92 | ESR1 (1.00) | ESR1MAPTLMNAHSD17B10MEN1 | |
| Dienestrol SCHEMBL2896848 | 0.92 | ESR1 (1.00) | ESR1MAPTLMNAHSD17B10MEN1 | |
| Dienestrol SCHEMBL52170 | 0.92 | ESR1 (1.00) | ESR1MAPTLMNAHSD17B10MEN1 | |
| Dienestrol SCHEMBL8425094 | 0.90 | ESR1 (0.85) | ESR1MAPTLMNAHSD17B10MEN1 | |
| Dienestrol SCHEMBL9317394 | 0.90 | ESR1 (0.94) | ESR1MAPTLMNAHSD17B10MEN1 | |
| Dienestrol SCHEMBL114016 | 0.88 | ESR1 (0.81) | ESR1MAPTLMNAHSD17B10MEN1 | |
| Dienestrol SCHEMBL3716190 | 0.87 | ESR1 (0.90) | ESR1MAPTLMNAHSD17B10MEN1 | |
| SCHEMBL13492676 | 0.83 | MAPT (0.81) | ESR1MAPTLMNAHSD17B10MEN1 | |
| SCHEMBL15721373 | 0.82 | MAPT (0.71) | ESR1MAPTLMNAHSD17B10MEN1 | |
| Dienestrol SCHEMBL8854079 | 0.82 | ESR1 (0.71) | ESR1MAPTLMNAHSD17B10MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1409512-A1 | 20-FLUORO-17(20)-VINYL STEROIDS AS INHIBITORS OF C17-20-LYASE AND 5-ALPHA REDUCTASE | Aventis Pharma S.A. (FR) | 2004-04-21 | — | — | EP | disclosed |
| US-6413951-B2 | ENZYME INHIBITOR | AVENTIS PHARMACEUTICALS, INC. | 2002-07-02 | — | — | US | disclosed |
| US-20020019548-A1 | 20-Fluoro-17(20)-vinyl steroids | AVENTIS PHARMA S.A. (FR) | 2002-02-14 | — | — | US | disclosed |
| WO-2002000681-A1 | 20-FLUORO-17(20)-VINYL STEROIDS AS INHIBITORS OF C17-20-LYASE AND 5-ALPHA REDUCTASE | AVENTIS PHARMA S.A. (FR) | 2002-01-03 | — | — | WO | disclosed |
| US-4080334-A | Intermediates in the total synthesis employing substituted isoxazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 1978-03-21 | — | — | US | disclosed |
| US-4044004-A | Total steroid synthesis employing substituted isoxazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 1977-08-23 | — | — | US | disclosed |
| US-3985771-A | Total steroid synthesis employing substituted isoxazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 1976-10-12 | — | — | US | disclosed |
| US-3984428-A | Isoxazolyl-substituted perhydrobenzindenes | HOFFMANN-LA ROCHE INC. (US) | 1976-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020019548-A1 | 20-Fluoro-17(20)-vinyl steroids | CYP17A1, HSD17B11, HSD3B1 | ESR1 111/4885MAPT 2727/4885LMNA 4392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.